|
1
|
Vallat-Decouvelaere AV, Wassef M, Lot G,
Catala M, Moussalam M, Caruel N and Mikol J: Spinal melanotic
schwannoma: A tumour with poor prognosis. Histopathology.
35:558–566. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rodriguez FJ, Folpe AL, Giannini C and
Perry A: Pathology of peripheral nerve sheath tumors: Diagnostic
overview and update on selected diagnostic problems. Acta
Neuropathol. 123:295–319. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Louis DN, Perry A, Reifenberger G, von
Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD,
Kleihues P and Ellison DW: The 2016 world health organization
classification of tumors of the central nervous system: A summary.
Acta Neuropathol. 131:803–820. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chawla SP, Chawla NS, Quon D, Chua-Alcala
V, Blackwelder WC, Hall FL and Gordon EM: An advanced phase 1/2
study using an XC-targeted gene therapy vector for chemotherapy
resistant sarcoma. Sarcoma Res Int. 3:10242016.
|
|
5
|
Gordon EM, Cornelio GH, Lorenzo CC III,
Levy JP, Reed RA, Liu L and Hall FL: First clinical experience
using a ‘pathotropic’ injectable retroviral vector (Rexin-G) as
intervention for stage IV pancreatic cancer. Int J Oncol.
24:177–185. 2004.PubMed/NCBI
|
|
6
|
Er U, Kazanci A, Eyriparmak T, Yigitkanli
K and Senveli E: Melanotic schwannoma. J Clin Neurosci. 14:676–678.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kurtkaya-Yapicier O, Scheithauer B and
Woodruff JM: The pathobiologic spectrum of Schwannomas. Histol
Histopathol. 18:925–934. 2003.PubMed/NCBI
|
|
8
|
Welling LC, Guirado VM, Tessari M, Felix
AR, Zanellato C, Figueiredo EG, Taricco MA and Teixeira MJ: Spinal
melanotic schwannomas. Arq Neuropsiquiatr. 70:156–157. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Faria MH, Dória-Netto RH, Osugue GJ, Lde S
Queiroz and Chaddad-Neto FE: Melanotic schwannoma of the cervical
spine progressing with pulmonary metastasis: Case report. Neurol
Med Chir (Tokyo). 53:712–716. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pan SY, Cheng YC and Kao TH:
Intramedullary melanotic schwannoma: Case report and review of the
literature. Surg Neurol Int. 5 Suppl 4:S181–S184. 2014. View Article : Google Scholar
|
|
11
|
Khoo M, Pressney I, Hargunani R and
Tirabosco R: Melanotic schwannoma: An 11-year case series. Skeletal
Radiol. 45:29–34. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Torres-Mora J, Dry S, Li X, Binder S, Amin
M and Folpe AL: Malignant melanotic schwannian tumor: A
clinicopathologic, immunohistochemical, and gene expression
profiling study of 40 cases, with a proposal for the
reclassification of ‘melanotic schwannoma’. Am J Surg Pathol.
38:94–105. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Röhrich M, Koelsche C, Schrimpf D, Capper
D, Sahm F, Kratz A, Reuss J, Hovestadt V, Jones DT,
Bewerunge-Hudler M, et al: Methylation-based classification of
benign and malignant peripheral nerve sheath tumors. Acta
Neuropathol. 131:877–887. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Küsters-Vandevelde HV, van Engen-van
Grunsven IA, Küsters B, van Dijk MR, Groenen PJ, Wesseling P and
Blokx WA: Improved discrimination of melanotic schwannoma from
melanocytic lesions by combined morphological and GNAQ mutational
analysis. Acta Neuropathol. 120:755–764. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Huang HY, Park N, Erlandson RA and
Antonescu CR: Immunohistochemical and ultrastructural comparative
study of external lamina structure in 31 cases of cellular,
classical, and melanotic schwannomas. Appl Immunohistochem Mol
Morphol. 12:50–58. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Killeen RM, Davy CL and Bauserman SC:
Melanocytic schwannoma. Cancer. 62:174–183. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hall FL, Liu L, Zhu NL, Stapfer M,
Anderson WF, Beart RW and Gordon EM: Molecular engineering of
matrix-targeted retroviral vectors incorporating a surveillance
function inherent in von Willebrand factor. Hum Gene Ther.
11:983–993. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chawla SP, Chua VS, Fernandez L, Quon D,
Blackwelder WC, Gordon EM and Hall FL: Advanced phase I/II studies
of targeted gene delivery in vivo: Intravenous Rexin-G for
gemcitabine-resistant metastatic pancreatic cancer. Mol Ther.
18:435–441. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gordon EM, Levy JP, Reed RA, Petchpud WN,
Liu L, Wendler CB and Hall FL: Targeting metastatic cancer from the
inside: A new generation of targeted gene delivery vectors enables
personalized cancer vaccination in situ. Int J Oncol. 33:665–675.
2008.PubMed/NCBI
|
|
20
|
Gordon EM, Lopez FF, Cornelio GH, Lorenzo
CC III, Levy JP, Reed RA, Liu L, Bruckner HW and Hall FL:
Pathotropic nanoparticles for cancer gene therapy Rexin-G IV:
Three-year clinical experience. Int J Oncol. 29:1053–1064.
2006.PubMed/NCBI
|
|
21
|
Gordon EM and Hall FL: Rexin-G, a targeted
genetic medicine for cancer. Expert Opin Biol Ther. 10:819–832.
2010. View Article : Google Scholar : PubMed/NCBI
|
